Want to see NAUT full AI Analyst Report?
Top Page
Nautilus Biotechnolgy
(NASDAQ:NAUT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▼(-33.99% Downside)
Action:Reiterated
Date:06/30/26
The score is held back primarily by weak financial performance (no revenue, large ongoing losses, and sustained cash burn) and limited valuation support due to a negative P/E and no dividend. Offsetting these negatives, the earnings call indicated tangible technical/commercial progress, improving expense discipline, and a cash runway through 2027, which reduces near-term financing risk but does not eliminate execution and timing risk.
Positive Factors
Differentiated proteomics platform
Nautilus's ability to generate proteoform-level, single-molecule data that collaborators could not access previously creates a durable scientific moat. This differentiation supports high-value partnerships, publications, and training of proprietary AI models, strengthening long-term demand for its instruments, assays, and consumables.
Negative Factors
No revenue and sustained cash burn
Persistent zero revenue and large negative operating cash flows indicate the business remains pre-commercial and capital reliant. Continued cash burn erodes equity and forces reliance on external funding or dilution if commercialization is delayed, constraining long-term investment in scale and market expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated proteomics platform
Nautilus's ability to generate proteoform-level, single-molecule data that collaborators could not access previously creates a durable scientific moat. This differentiation supports high-value partnerships, publications, and training of proprietary AI models, strengthening long-term demand for its instruments, assays, and consumables.
Read all positive factors
Nautilus Biotechnolgy (NAUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$237.64M
Dividend YieldN/A
Average Volume (3M)394.63K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue GrowthN/A
EPS Growth17.33%
CountryUS
Employees130
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding127,078,860
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-95.06
Enterprise Value/Ebitda-5.74
Forecast
1Y Price Target
$4.00Price Target Upside32.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$700.00K
Nautilus Biotechnolgy Business Overview & Revenue Model
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, w...
How the Company Makes Money
null...
Nautilus Biotechnolgy Earnings Call Summary
Earnings Call Date:Apr 28, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call emphasized substantive technical and commercial progress: verified service lab, strong scientific collaborator results (including novel ApoE–Tau proteoform findings), nearly tripled qualified probes, targeted oncology assay progress, and deliberate commercial hires. Financially the company reduced operating expenses YoY and exited the quarter with $143.4M in cash and a stated runway through 2027. Offsetting these positives are external delays (Middle East conflict) that pushed grant revenue recognition and some reagent development later in the year, a nascent sales pipeline with only one named EAP customer so far, remaining verification/validation work before broadscale customer deployments, and modest expected revenue (~$0.5M) for 2026. On balance, accomplishments materially outweigh the challenges but execution and timing risks remain.Positive Updates
Early Access Program Launch and Strategic Collaborations
Launched Iterative Mapping Early Access Program in January 2026 and debuted the Voyager platform at US HUPO; established collaborations including the Michael J. Fox Foundation/Weill Cornell Medicine-Qatar alpha-synuclein program and ongoing work with Buck Institute and Allen Institute, enabling unique proteoform-level biological insights.
Negative Updates
Revenue and Grant Recognition Delays
Revenue recognition tied to the Michael J. Fox Foundation grant progressed more slowly than anticipated due to delays related to the ongoing conflict in the Middle East; company now expects approximately $0.5M in total revenue for the year with a greater portion shifting into later quarters.
Read all updates
Q1-2026 Updates
Positive
Negative
Early Access Program Launch and Strategic Collaborations
Launched Iterative Mapping Early Access Program in January 2026 and debuted the Voyager platform at US HUPO; established collaborations including the Michael J. Fox Foundation/Weill Cornell Medicine-Qatar alpha-synuclein program and ongoing work with Buck Institute and Allen Institute, enabling unique proteoform-level biological insights.
Read all positive updates
Company Guidance
Nautilus reiterated a detailed commercialization timetable and metric-backed progress: it plans to expand Iterative Mapping Early Access in H2 2026 with a second (oncology) proteoform assay, introduce broadscale capabilities into early access later in 2026, begin beta Voyager placements in late Q3/Q4 2026, open preorders in late 2026 with customer installations starting in early 2027 and general availability of broadscale capabilities in H1 2027. Operationally, the company has one named EAP customer (Baylor College of Medicine), active collaborations with the Buck Institute, Allen Institute and Neural Stem Cell Institute, an Alpha instrument in the field for ~1 year, a sales team of three (VP Amber Faust +2 hires), a service lab that passed verification/validation (meeting accuracy, dynamic range, reproducibility and stability requirements), nearly tripled the number of probes qualified as assay-compatible this quarter and completed its largest number of high‑cycle decode experiments while routinely testing lysate mixtures and full lysates. Financially, Q1 operating expenses were $16.1M (R&D $9.7M, down 16% Y/Y; G&A $6.4M, down 12% Y/Y), Q1 cash burn was $12.8M (including $1.1M from option exercises), cash and investments were $143.4M at quarter end, management expects roughly $0.5M revenue for the year (shifted into later quarters) and believes the cash runway extends through 2027.Nautilus Biotechnolgy Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.06M | -6.46M | -6.35M | -5.71M | -3.42M | -2.84M |
| EBITDA | -50.77M | -52.54M | -64.43M | -61.83M | -54.51M | -47.47M |
| Net Income | -57.09M | -59.00M | -70.78M | -63.67M | -57.92M | -50.31M |
Balance Sheet | ||||||
| Total Assets | 177.78M | 191.11M | 242.74M | 305.56M | 350.05M | 398.45M |
| Cash, Cash Equivalents and Short-Term Investments | 95.87M | 103.41M | 129.89M | 173.42M | 184.47M | 345.73M |
| Total Debt | 28.87M | 30.02M | 30.48M | 34.63M | 30.33M | 30.03M |
| Total Liabilities | 33.36M | 34.14M | 34.01M | 40.21M | 35.13M | 34.87M |
| Stockholders Equity | 144.41M | 156.97M | 208.73M | 265.35M | 314.92M | 363.58M |
Cash Flow | ||||||
| Free Cash Flow | -51.43M | -51.97M | -61.27M | -54.15M | -48.13M | -41.51M |
| Operating Cash Flow | -49.86M | -50.70M | -59.15M | -51.71M | -45.81M | -39.24M |
| Investing Cash Flow | 29.95M | 35.22M | 66.25M | -43.73M | -25.74M | -138.96M |
| Financing Cash Flow | 1.30M | 214.00K | 1.14M | 368.00K | 562.00K | 327.45M |
Nautilus Biotechnolgy Technical Analysis
Negative
3.03
Price Trends
2.52
Negative
2.67
Negative
2.14
Negative
Market Momentum
-0.12
Positive
32.73
Neutral
51.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Negative. The current price of 3.03 is above the 20-day moving average (MA) of 2.28, above the 50-day MA of 2.52, and above the 200-day MA of 2.14, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 32.73 is Neutral, neither overbought nor oversold. The STOCH value of 51.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAUT.
Nautilus Biotechnolgy Risk Analysis
Nautilus Biotechnolgy disclosed 68 risk factors in its most recent earnings report. Nautilus Biotechnolgy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nautilus Biotechnolgy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $237.64M | -4.02 | -35.04% | ― | ― | 17.33% | |
46 Neutral | $88.84M | -1.87 | -72.78% | ― | ― | 73.91% | |
46 Neutral | $91.82M | -1.35 | -26.58% | ― | -1.44% | 11.50% | |
46 Neutral | $192.85M | -1.44 | -123.07% | ― | ― | 3.91% | |
43 Neutral | $9.27M | -0.12 | ― | ― | ― | ― |
* Healthcare Sector Average
NAUT
Nautilus Biotechnolgy
1.87
1.14
156.16%
VTGN
VistaGen Therapeutics
0.23
-1.78
-88.76%
KLRS
Kalaris Therapeutics
4.07
1.49
57.75%
SEER
Seer
1.66
-0.53
-24.20%
ABOS
Acumen Pharmaceuticals
2.67
1.56
140.54%
Nautilus Biotechnolgy Corporate Events
Executive/Board ChangesShareholder Meetings
Nautilus Biotech stockholders approve directors and governance items
Positive
Jun 18, 2026
Nautilus Biotechnology, Inc. held its 2026 annual meeting of stockholders on June 17, 2026, with 85,002,191 of 127,078,855 eligible shares represented, and stockholders elected Parag Mallick and Farzad Nazem as Class II directors to serve until th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.